Italia markets closed

Ionis Pharmaceuticals, Inc. (0JDI.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
42,25-0,10 (-0,23%)
Alla chiusura: 06:58PM BST
Schermo intero
Chiusura precedente42,35
Aperto42,18
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno42,16 - 42,18
Intervallo di 52 settimane33,21 - 53,94
Volume0
Media Volume351
Capitalizzazione58,522M
Beta (5 anni mensile)0,40
Rapporto PE (ttm)N/D
EPS (ttm)-0,03
Prossima data utili01 mag 2024 - 06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

    Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for ulixacaltamide initiating this quarter with mADL11 as primary endpoint; nearly 600 patients have already expressed interest in participating BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insigh

  • GlobeNewswire

    New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

    Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec)Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experience CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community.